Crypto crash wrap: Bitcoin, Ethereum lead $560B market bloodbath after tariff news

Crypto crash wrap: Bitcoin, Ethereum lead $560B market bloodbath after tariff news

The cryptocurrency market took a wild hit, as President Donald Trump’s sudden announcement of a 100% tariff on Chinese tech imports sparked a massive sell-off. This unexpected move dramatically escalated trade tensions, rattling investor confidence and triggering a heavy bloodbath across major cryptocurrencies. The shock sent prices tumbling, wiping out billions in market value and […]

Read More
 EchoStar surges on $17 billion spectrum deal with SpaceX; analysts say sale neutral

EchoStar surges on $17 billion spectrum deal with SpaceX; analysts say sale neutral

Shares of EchoStar jumped more than 17% on Monday after the telecommunications company unveiled a $17 billion deal with SpaceX to sell its AWS-4 and H-block spectrum licenses. The agreement marks the firm’s second major spectrum transaction in recent weeks, further strengthening its balance sheet while advancing SpaceX’s ambitions in satellite-powered mobile connectivity. On August […]

Read More
 Evening digest: Israel strikes Doha, Nepal crisis, Elon Musk fined, Nvidia unveils Rubin CPX

Evening digest: Israel strikes Doha, Nepal crisis, Elon Musk fined, Nvidia unveils Rubin CPX

Tuesday’s global headlines highlight sharp escalation of tensions with Israel ordering a bold strike on Hamas leaders in Qatar while political unrest forced Nepal’s prime minister to resign. Elon Musk is facing a new headache in Canada and Nvidia’s Rubin CPX chip promising AI advancements. A glance at the biggest stories capturing attention today. Israel’s […]

Read More
 Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Teva Pharmaceutical Industries Ltd. stock rose 12% after the company reported stronger-than-expected third-quarter results, buoyed by robust growth in its branded drug portfolio. The Tel Aviv-based pharmaceutical giant’s shift toward innovative medicines appears to be paying off, even as its core generics business continues to face challenges. Branded drug portfolio drives earnings beat Teva posted […]

Read More